- Report
- January 2024
- 113 Pages
United States
€3117EUR$3,500USD£2,696GBP
- Report
- October 2023
- 85 Pages
United States
From €4320EUR$4,850USD£3,736GBP
- Report
- July 2023
- 218 Pages
Global
From €4008EUR$4,500USD£3,467GBP
- Report
- March 2023
- 30 Pages
Global
€10911EUR$12,250USD£9,437GBP
- Report
- April 2018
United States
From €7121EUR$7,995USD£6,159GBP
- Report
- October 2022
- 145 Pages
Global
From €1781EUR$2,000USD£1,541GBP
- Report
- October 2024
- 83 Pages
Global
From €3500EUR$4,210USD£3,133GBP
Ixekizumab is a monoclonal antibody used to treat immune disorders. It is a type of biologic drug, which is a medication derived from living cells. It works by blocking the action of a protein called interleukin-17A (IL-17A), which is involved in inflammation. Ixekizumab is used to treat psoriasis, an autoimmune disorder that causes red, scaly patches on the skin, and psoriatic arthritis, a type of arthritis that affects people with psoriasis. It is also used to treat ankylosing spondylitis, a type of arthritis that affects the spine.
Ixekizumab is administered as an injection under the skin. It is available in both brand-name and generic forms. It is typically used in combination with other medications, such as methotrexate or corticosteroids.
Ixekizumab is manufactured by several companies, including Eli Lilly, Amgen, and Novartis. It is also available as a generic drug from several generic drug manufacturers. Show Less Read more